Maintenance Therapy Post-HSCT in High-risk Aggressive Lymphoma

Phase 2/3 Unknown 60 enrolled Fujian Medical University

Non-randomizedParallel-groupOpen-labelPrevention

Summary

Relapse after autologous hematopoietic stem cell transplantation (ASCT) is still challenging for high-risk aggressive lymphoma. This study was to investigate the efficacy and safety of maintenance therapy post-ASCT.

Timeline

Start: 2014-01
Primary completion: 2020-01
Completion: 2023-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rituximab	Monoclonal antibody	—	—

Maintenance Therapy Post-HSCT in High-risk Aggressive Lymphoma

Summary

Timeline

Drugs

Indications